Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
Eliano Pio Navarese, Przemysław Podhajski, Paul A. Gurbel, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 3, pp. 224-234
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Xuhui Bao, Yongjun Liang, Hanman Chang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 40
Vascular leak in sepsis: physiological basis and potential therapeutic advances
Ross R. McMullan, Daniel F. McAuley, Cecilia M. O’Kane, et al.
Critical Care (2024) Vol. 28, Iss. 1
Open Access | Times Cited: 16
Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
Khursheed Muzammil, Mohammad Hosseini Hooshiar, Shirin Varmazyar, et al.
Microbial Cell Factories (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Preparing for the next viral threat with broad-spectrum antivirals
Marwah Karim, Chieh‐Wen Lo, Shirit Einav
Journal of Clinical Investigation (2023) Vol. 133, Iss. 11
Open Access | Times Cited: 24
Cholesterol and COVID-19—therapeutic opportunities at the host/virus interface during cell entry
Thomas Grewal, Mai Khanh Linh Nguyen, Christa Buechler
Life Science Alliance (2024) Vol. 7, Iss. 5, pp. e202302453-e202302453
Open Access | Times Cited: 8
The bidirectional interaction of COVID-19 infections and lipoproteins
Kenneth R. Feingold
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 4, pp. 101751-101751
Open Access | Times Cited: 19
Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia
Chel Hee Lee, Mohammad Mehdi Banoei, Mariam Ansari, et al.
Critical Care (2024) Vol. 28, Iss. 1
Open Access | Times Cited: 5
PCSK9 potentiates innate immune response to RNA viruses by preventing AIP4-mediated polyubiquitination and degradation of VISA/MAVS
Fang Han, Meng-Ling Shi, Cong Wang, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 8
Open Access
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
Csaba Mátyás, Eszter Trojnár, Suxian Zhao, et al.
JACC Basic to Translational Science (2023) Vol. 8, Iss. 10, pp. 1334-1353
Open Access | Times Cited: 12
Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review
Hina Arsh, FNU Manoj Kumar, FNU Simran, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 2, pp. 899-908
Open Access | Times Cited: 4
Plasma Protein Biomarkers Distinguish Multisystem Inflammatory Syndrome in Children From Other Pediatric Infectious and Inflammatory Diseases
Sophya Yeoh, Diego Estrada‐Rivadeneyra, Heather Jackson, et al.
The Pediatric Infectious Disease Journal (2024) Vol. 43, Iss. 5, pp. 444-453
Open Access | Times Cited: 4
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition
Alexander M. Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 10
Closed Access | Times Cited: 4
The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials
Zhen Zhou, Wei Zhang, David Burgner, et al.
The American Journal of Medicine (2023) Vol. 136, Iss. 6, pp. 558-567.e20
Open Access | Times Cited: 10
Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects
Robert S. Rosenson, Ashley Tate, Phyu Mar, et al.
Atherosclerosis (2024) Vol. 392, pp. 117529-117529
Open Access | Times Cited: 3
Proteomic mapping identifies serum marker signatures associated with MIS-C specific hyperinflammation and cardiovascular manifestation
Andrea Reiter, Emely Verweyen, Emmanuelle Queste, et al.
Clinical Immunology (2024) Vol. 264, pp. 110237-110237
Open Access | Times Cited: 3
The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy
Chou‐Yi Hsu, Mustafa Nasrat Abdulrahim, Mohammed Ahmed Mustafa, et al.
Medical Oncology (2024) Vol. 41, Iss. 8
Closed Access | Times Cited: 3
Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19
Patricia Mester, Pablo Amend, Stephan Schmid, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1511-1511
Open Access | Times Cited: 9
SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2
Rachid Essalmani, Ursula Andréo, Alexandra Evagelidis, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 360-360
Open Access | Times Cited: 8
Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels
Patricia Mester, Pablo Amend, Stephan Schmid, et al.
Infectious Disease Reports (2024) Vol. 16, Iss. 4, pp. 593-607
Open Access | Times Cited: 2
The impact of statin therapy on in‐hospital prognosis and endothelial function of patients at high‐to‐very high cardiovascular risk admitted for COVID‐19
Vanessa Bianconi, Massimo R. Mannarino, Elena Cosentini, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 7
Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis
Muttanagouda Giriyappagoudar, Basavaraj Vastrad, Rajeshwari Horakeri, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3109-3109
Open Access | Times Cited: 7
PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
Sascha N. Goonewardena, Robert S. Rosenson
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 3, pp. 235-236
Open Access | Times Cited: 6
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19
Alpo Vuorio, Frederick J. Raal, Petri T. Kovanen
Current Opinion in Lipidology (2023) Vol. 34, Iss. 3, pp. 119-125
Closed Access | Times Cited: 5
Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
Alpo Vuorio, Petri T. Kovanen, Frederick J. Raal
Annals of Medicine (2023) Vol. 55, Iss. 1
Open Access | Times Cited: 5
Adjunctive therapy with lipid-lowering agents in COVID-19: a systematic review and meta-analysis of randomized controlled trials
Amirmohammad Khalaji, Amir Hossein Behnoush, Sanam Alilou, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top